Ofev 150 mg Soft Capsules Buy – Nintedanib

Ofev 150 mg Soft Capsules, containing the active ingredient Nintedanib, is an advanced oral medication developed by Boehringer Ingelheim. It is widely recognized as a disease-modifying agent in the treatment of Idiopathic Pulmonary Fibrosis (IPF), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), and other progressive fibrosing interstitial lung diseases (PF-ILD). Ofev works by inhibiting multiple tyrosine kinases involved in lung tissue scarring and fibrosis, helping to slow disease progression and preserve lung function.

Key Features and Benefits:

• Active Ingredient: Nintedanib – 150 mg per soft capsule.
• Pack Size: 60 soft capsules per box.
• Manufacturer: Boehringer Ingelheim – Renowned German pharmaceutical company with global trust.
• Indications:
  • Idiopathic Pulmonary Fibrosis (IPF): Slows the decline in lung function.
  • Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Reduces lung fibrosis progression.
  • Other Progressive Fibrosing Interstitial Lung Diseases (PF-ILD): Slows the rate of disease advancement.
• Mechanism of Action:
  Nintedanib is a triple angiokinase inhibitor, targeting VEGFR, FGFR, and PDGFR receptors. It blocks signaling pathways involved in fibroblast proliferation, migration, and differentiation, which are key processes in lung tissue fibrosis.
• Clinically Proven Efficacy:
  • Slows Forced Vital Capacity (FVC) decline in IPF and SSc-ILD patients.
  • Reduces lung function deterioration in PF-ILD cases.
  • Provides consistent benefits across diverse patient populations.
• Convenient Oral Therapy: Soft capsules ensure ease of swallowing and consistent daily dosing.

How Does Ofev (Nintedanib) Work?

Ofev targets the underlying processes of lung fibrosis by inhibiting tyrosine kinase receptors involved in the formation of fibrotic tissue. By blocking the activation of these growth factors (VEGFR, FGFR, PDGFR), it slows the excessive formation of scar tissue in the lungs, helping patients breathe more easily and maintain lung function for a longer period.

Dosage and Administration:

• Recommended Dose: 150 mg twice daily (every 12 hours).
• Administration:
  • Take with food to reduce gastrointestinal side effects.
  • Swallow the capsule whole with water; do not crush or chew.
• Dose Adjustments:
  • May be reduced to 100 mg twice daily in case of intolerable side effects.
  • Temporary treatment interruptions may be required if severe adverse effects occur.

Safety Information and Precautions:

• Gastrointestinal Side Effects:
  • Diarrhea is the most common side effect; ensure adequate hydration.
  • Nausea, vomiting, and abdominal pain can occur.
• Hepatic Function:
  • Regular liver function tests are recommended.
  • Patients with severe liver impairment should not use Ofev.
• Bleeding Risk:
  • Caution in patients with bleeding disorders or taking anticoagulants.
• Cardiovascular Risk:
  • Monitor patients with pre-existing heart disease.
  • Risk of arterial thromboembolic events (e.g., stroke, myocardial infarction).
• Pregnancy and Fertility:
  • Not recommended for pregnant women.
  • Women of childbearing potential should use effective contraception.

Special Warnings:

• Avoid Grapefruit Juice:
  • Grapefruit may interfere with Ofev metabolism.
• Smoking:
  • Smoking may reduce Nintedanib effectiveness.
• Patients Aged 65 and Above:
  • No specific dose adjustment is required, but monitoring is advised.

Why Choose Ofev (Nintedanib) 150 mg?

• FDA and EMA Approved: For Idiopathic Pulmonary Fibrosis (IPF) and SSc-ILD.
• Disease Progression Slowing: Reduces lung function decline across multiple forms of pulmonary fibrosis.
• Comprehensive Fibrosis Inhibition: Targets multiple growth factors associated with lung scarring.
• Trusted Manufacturer: Boehringer Ingelheim – Over 130 years of pharmaceutical innovation.

Storage Instructions:

• Store below 25°C.
• Keep in original packaging to protect from moisture.
• Keep out of reach of children.

Who Can Benefit from Ofev?

• Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF).
• Individuals with Systemic Sclerosis-associated ILD (SSc-ILD).
• Patients suffering from other progressive fibrosing ILDs.

Manufacturer Information:

• Brand: Ofev 150 mg Soft Capsules.
• Active Substance: Nintedanib.
• Presentation: 60 Soft Capsules per Box.
• Manufacturer: Boehringer Ingelheim, Germany.

Ordering Ofev 150 mg Online:

Get Ofev (Nintedanib) 150 mg from our trusted online pharmacy. Benefit from global delivery, competitive pricing, and genuine pharmaceutical products, ensuring fast and reliable service.